Ed. note: A continuation of the monthly “Gratitude Miniseries.” As September drew to a close, I was preparing this column by intending to say the month was full of all good things. That was before I learned that a close friend and colleague had died of complications…
Combining Ofev (nintedanib, marketed by Boehringer Ingelheim) with sildenafil does not offer additional clinical benefits when compared to Ofev treatment alone regarding quality of life and lung function in patients with idiopathic…
Veracyte will present new results that showcase the ability of the Envisia Genomic Classifier to provide reliable data that helps physicians diagnose interstitial lung disease (ILD) — including idiopathic pulmonary fibrosis (IPF) — at CHEST 2018 meeting. Veracyte also will present new results about the capability of the…
I am writing this column from my hospital room, and I’m feeling pretty frustrated. As I was rushing into the grocery store this evening with my oxygen tank strapped to my back and a million things on my mind, I unfortunately didn’t notice the person smoking right outside…
A recent study in mice shows that endometrial regenerative cells (ERCs) can ease some of the common symptoms of idiopathic pulmonary fibrosis (IPF). Titled “Human Endometrial Regenerative Cells Attenuate Bleomycin-Induced Pulmonary Fibrosis in Mice,” the study was recently published in the journal Stem Cells International. Therapeutic…
Treatment with Esbriet (pirfenidone) or Ofev (nintedanib) significantly slowed the progression of idiopathic pulmonary fibrosis (IPF) in a real-life clinical setting, an Italian study reported. The study, “Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre” was published in the journal…
I understand that it is uncommon to see a young adult wearing supplemental oxygen and using a wheelchair due to fatigue. It might spark a passerby’s curiosity about what has made this young person’s lungs so sick that they can’t breathe efficiently. I understand curiosity, but as…
Samumed and United Therapeutics announced an exclusive license agreement for North American rights to Samumed’s investigational therapy SM04646 to treat idiopathic pulmonary fibrosis (IPF). Under the agreement, United Therapeutics will pay Samumed $10 million up-front, plus up to $340 million in developmental milestones in addition to other…
Treating one’s self with tender care is especially important to pulmonary fibrosis patients and their families. Medical tests, clinic visits, long-term illness management, and a shortened lifespan are difficult, unpleasant, and stressful experiences. We continue to grieve and adjust as our lungs worsen. It is important to respond…
Corbus Pharmaceuticals has acquired from Jenrin Discovery more than 600 compounds designed to target the endocannabinoid system, including CRB-4001 for the treatment of fibrotic diseases affecting the lungs, liver, heart, and kidney. The endocannabinoid system is associated with the resolution (or shutting off) of the inflammatory response, which…
Get regular updates to your inbox.
